risks of microdosing

Psilocybin, the psychoactive compound found in certain species of mushrooms, has gained considerable attention for its potential therapeutic benefits. However, it is important to recognize that psilocybin use, including microdosing, carries inherent risks. In this comprehensive blog post, we will explore the potential risks associated with psilocybin use and microdosing. By understanding these risks, individuals can make informed decisions and approach these practices responsibly. Let’s delve into the topic and discuss key points:

I. Understanding Psilocybin and Microdosing:

  • Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, known colloquially as magic mushrooms or shrooms.
  • Microdosing involves taking sub-perceptual doses of psilocybin to tap into potential benefits while minimizing the psychedelic effects.

II. Examining the Risks:

  1. Psychological Effects and Mental Health:
    • Psilocybin can induce intense psychological experiences, which may include challenging or adverse reactions, especially in vulnerable individuals. These challenging experiences can range from confronting deep-seated emotions and traumatic memories to experiencing a loss of ego or a sense of dissolution of self. It is crucial to emphasize that these challenging reactions should not be taken lightly, and individuals should be prepared to face them with proper professional support.
  2. Individual Variability and Sensitivities:
    • Individual responses to psilocybin can vary significantly due to factors such as genetics, mental health history, and personality traits.
    • It is crucial to recognize that what may be a positive experience for one person may be distressing for another.
  3. Potential Risks for Vulnerable Populations:
    • Individuals with pre-existing mental health conditions, such as anxiety disorders, schizophrenia, or bipolar disorder, may be at increased risk when using psilocybin.
    • The importance of professional guidance and supervision for individuals with underlying mental health concerns cannot be emphasized enough.
  4. Legal and Ethical Considerations:
    • Psilocybin is classified as a Schedule I substance in many countries, meaning it is illegal and considered to have no accepted medical use and a high potential for abuse (United States Drug Enforcement Administration, n.d.).
    • Understanding and adhering to the legal framework and ethical considerations surrounding psilocybin use is essential to avoid legal consequences and promote responsible behavior.

III. Mitigating Risks and Promoting Responsible Practices:

  1. Seeking Professional Guidance:
    • It is highly recommended to consult with healthcare professionals or qualified therapists experienced in psychedelic-assisted therapy when considering psilocybin use or microdosing.
    • Professional guidance can help individuals navigate potential risks, set appropriate intentions, and integrate experiences effectively.
  2. Educating Yourself:
    • It is essential to educate yourself about the potential risks and benefits of psilocybin through reliable sources such as scientific studies, reputable publications, and respected organizations in the field.
    • Being well-informed allows for better decision-making and a deeper understanding of the complexities involved.


Psilocybin use and microdosing hold promise as tools for personal growth and therapeutic exploration. However, it is essential to recognize and understand the potential risks involved. By embracing responsible practices, seeking professional guidance, and being aware of legal and ethical considerations, individuals can approach psilocybin use and microdosing with greater awareness, safety, and respect. Remember, this blog post is not a substitute for professional medical advice, and it is important to consult with healthcare professionals before making decisions regarding psilocybin use or microdosing. If you have any questions regarding psilocybin abuse for yourself or a loved one, feel free to reach out to us here at PCI Centers.

PCI Centers understands your situation and is here to assist you. We provide the most current substance use treatment options, as well as a caring and supportive environment. Our expert team will collaborate with you to develop a personalized treatment plan that meets your specific needs. Please contact us today to learn more about how we can assist you in overcoming your substance use issues.

We are committed to helping you on your journey and will walk alongside you every step of the way. Call us at (818) 629-2176 or come by our Westlake Village of Malibu location for a tour and an introductory meeting to get started. We look forward to hearing from you soon.



Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., … & Nutt, D. J. (2016). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 6(1), 1-11.

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197.

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71-78.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983-992.

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83-102.

United States Drug Enforcement Administration. (n.d.). Drug scheduling. Retrieved from https://www.dea.gov/drug-scheduling

Watts, R., Luoma, J. B., & Frohoff, C. (2017). Psychedelics and psychological flexibility: Examining the effects of psilocybin for psychological distress in the context of a mindfulness-based intervention. Journal of Cognitive Enhancement, 1(3), 3-13.